Posts filed under: News

Melbourne (Australia) – 3rd December 2018. Telix Pharmaceuticals Limited is pleased to provide investors an audio link to the Investor Conference Call hosted by the Company and led by Managing...
Continue Reading →
Melbourne (Australia), Brussels and Liège (Belgium) – 26th November 2018. Telix Pharmaceuticals Limited today announced that it has acquired Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA. To facilitate shareholder queries,...
Continue Reading →
Melbourne (Australia), Brussels and Liège (Belgium) – 26th November 2018. Telix Pharmaceuticals Limited today announced that it has acquired Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA. The full media release...
Continue Reading →
Melbourne (Australia), Brussels and Liège (Belgium) – 26th November 2018. Telix Pharmaceuticals Limited today announced that it has acquired Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA. To facilitate shareholder queries,...
Continue Reading →
Melbourne (Australia), Brussels and Liège (Belgium) – 26th November 2018. Telix Pharmaceuticals Limited today announced that it has acquired Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA. For market briefing click...
Continue Reading →
Melbourne (Australia), Brussels (Belgium) – 18th of October 2018. Telix Pharmaceuticals Limited has today announced that the Company has received its first European Competent Authority (CA) approval to commence a...
Continue Reading →
Melbourne (Australia) and Nijmegen (the Netherlands) – 17 October 2018. Telix Pharmaceuticals Limited announced that it has concluded a GMP manufacturing agreement with Radboud Translational Medicine B.V. The full media...
Continue Reading →
Melbourne (Australia) and Seibersdorf (Austria) – 16 October 2018. Telix Pharmaceuticals Limited announced that it has entered into a commercial manufacturing agreement with Seibersdorf Labor GmbH. The full media release...
Continue Reading →
Melbourne (Australia) and Liège (Belgium) – 15 October 2018. Telix Pharmaceuticals Limited announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA for the 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA) cold...
Continue Reading →
Melbourne (Australia) – 15 October 2018. Telix Pharmaceuticals Limited announced an extension to its master service agreement (MSA) with Cyclotek (Aust) Pty Ltd to include 89Zr-Girentuximab (TLX250-CDx) for imaging patients...
Continue Reading →